# A Study of CTD402 in T-ALL/LBL Patients

Source: https://onco.cc/trials/nct07070219/  
OnCo record `nct07070219` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CTD402 CAR T Cell Injection in acute lymphoblastic leukaemia and non-Hodgkin lymphoma, run by Imviva Bio, now recruiting.

## Summary

A Study of CTD402 in T-ALL/LBL Patients is a phase 1/2 interventional study registered as NCT07070219 by Imviva Bio, with 118 participants planned, started 2025-10-07 and due to reach its primary completion in 2028-09-30. Interventions recorded: CTD402 CAR T Cell Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07070219
- Phase: 1/2
- Setting: A Single-Arm, Open-Label, Multi-Center, Phase 1b/ 2 Study to Evaluate the Safety, Efficacy, and Cellular Pharmacokinetic Profile of CTD402 in Participants With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) (TENACITY-01)
- Sponsor: Imviva Bio
- Enrolled: 118

## Sources

- ClinicalTrials.gov NCT07070219: https://clinicaltrials.gov/study/NCT07070219

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/nct07070219.json